Dongkuk Pharmaceutical's Uresko tablet, a treatment for benign prostatic hyperplasia, has achieved a 76.3% market share in the combination drug sector.
On September 24, Dongkuk Pharmaceutical announced that, according to market research firm UBIST, Uresko recorded a 76.3% share in the dutasteride and tadalafil combination drug market as of June. This figure places it at the top among similar products that were launched around the same time.
Uresko is the world's first combination tablet containing 0.5 mg of dutasteride and 5 mg of tadalafil. Dutasteride reduces prostate size and inhibits disease progression, while tadalafil improves urinary symptoms such as weak stream and residual urine, as well as storage symptoms like frequent urination and nocturia.
The efficacy and safety of Uresko were evaluated in a domestic multi-center Phase 3 clinical trial, the results of which were published in the British Journal of Urology International (BJU International). The study demonstrated that Uresko showed superior efficacy and acceptable safety compared to each individual component. Dongkuk Pharmaceutical explained that the simultaneous administration of both components can alleviate symptoms and provide long-term management of benign prostatic hyperplasia.
Dongkuk Pharmaceutical is also pursuing expansion into international markets. Recently, it signed a technology transfer and supply agreement with Spanish pharmaceutical company FAES FARMA for Uresko in 13 Latin American countries, including Mexico, Colombia, Ecuador, Peru, and Chile.
A company representative stated, "Since benign prostatic hyperplasia is a condition that requires long-term treatment, it is important to consider not only current symptoms but also prostate size, disease progression risk, patient age, and quality of life in treatment. As treatment goals vary according to patient characteristics, Uresko is strengthening its position as a new option that broadens the choices for treating benign prostatic hyperplasia in clinical practice."
Meanwhile, buoyed by rapid growth in its health and beauty (H&B) business, Dongkuk Pharmaceutical is on track to surpass 1 trillion won in annual revenue for the first time since its founding. If achieved, it will join the ranks of traditional Korean pharmaceutical companies, becoming the ninth to enter the '1 trillion club' alongside Yuhan Corporation and GC Green Cross.
For the first half of this year, Dongkuk Pharmaceutical reported consolidated revenues of 509.9 billion won, a 10.9% increase from the same period last year, and an operating profit of 53.4 billion won, up 12.6%. The market anticipates that the company's annual revenue will reach 1.0392 trillion won, a 12.1% increase from the previous year, with an operating profit of 104.5 billion won, an 8.2% rise.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.